GeNO LLC Announces Senior Management Appointments
12/19/2012 6:21:27 AM
Dasse named President; Gellman named Senior Vice President, Engineering
WALTHAM, Mass., Dec. 18, 2012 -- GeNO LLC, a privately held pharmaceutical company that is developing innovative nitric oxide (NO) generation and delivery platforms, today announced that Kurt Dasse, a member of the company's Board of Managers and formerly Executive Vice President, has been appointed President of GeNO. Prior to joining GeNO, he served as President and CEO of Waltham, Massachusetts based technology company Levitronix LLC.
In addition, Barry Gellman has been appointed Senior Vice President, Engineering, to focus on GeNO's research, development, and production.
"These appointments will help provide a strong foundation as we continue to develop and deliver innovative, cost-effective nitric oxide generation and delivery platforms for the treatment of multiple diseases and conditions," said David Fine, GeNO Founder, Chairman and CEO. "We have already realized significant milestones under Kurt's leadership. His vast experience in conducting research in cardiovascular disorders and developing medical devices has been invaluable. Barry's capabilities in developing ventricular assist devices combined with his extensive engineering and management expertise help to position GeNO very well for the future."
Dasse, who will continue to serve on the Company's Board of Managers, has spent nearly 30 years researching cardiovascular disorders and developing medical devices, including products to treat heart and renal failure. He joined GeNO as a member of the Board of Managers in 2007 and as Executive Vice President in 2011. Dasse founded Levitronix LLC in 2001 as the Chief Technical Officer, and became President & CEO in 2006. Earlier in his career, Dasse was Chief Scientist and Vice President of $700-million Thermo Electron Corporation's biomedical group. He also was one of the founding officers of Thermo Cardiosystems and played a key role in commercializing the first implantable ventricular assist system for end-stage heart-failure patients. Dasse received his doctorate in medical physiology from Boston University and his bachelor's degree in biology from the University of Massachusetts. He has written more than 100 journal articles and multiple book chapters, and holds numerous patents.
Gellman has devoted his 38 year career to biomedical engineering and management roles within several companies. At GeNO, Gellman will manage all research, development and production functions. He joins GeNO from Thoratec Corporation. He spent seven years as Vice President of Engineering in the medical division of Levitronix. In these roles, Gellman was responsible for engineering, management and strategic planning for mechanical circulatory support devices, including ventricular assist devices (VAD) and extracorporeal membrane oxygenator systems (ECMO). Gellman was Director of Research and Development and Chief Engineer of the urology and gynecology division for Boston Scientific Corporation, among other management roles during his 13 years with the company. Gellman received his Master of Science in mechanical engineering from the New Jersey Institute of Technology and his Bachelor of Science in the same discipline from the Newark College of Engineering. Gellman's extensive patent experience includes 90 US patents issued on his work, and 123 patent pending applications.
ABOUT GENO LLC
GeNO LLC, founded in 2006, is a privately held pharmaceutical company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the true potential of inhaled nitric oxide to be realized for the treatment of a multitude of diseases. The company is focused on applying its technology to delivering inhaled NO to patients in a variety of settings, including ambulatory and in-home use for potential chronic treatment. GeNO will provide stand-alone medical devices and combination products that include delivery systems and GeNO's nitric oxide gas. GeNO's nitric oxide delivery systems have been designated as combination products by the Food and Drug Administration (FDA) Office of Combination Products, with the Division of Cardiovascular and Renal Products designated as the lead reviewer. The combination products will be regulated by the FDA as new drugs with their own new drug applications.
Kellie Caldwell, 610-505-1511 email@example.com www.genollc.com
Brian Heffron, 781-799-9568